It has been proposed that platelet-derived growth factor receptors are key players in the chemoresistance of breast cancer caused by FOXQ1, which could have consequences for the evolution and maturation of novel therapeutic regimens for the disease [72]. This evidence concerns the gene FOXQ1 and breast carcinoma.